Influence of statins on MHC Class i expression

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 746-751

  Singh, Pratibha ^a   Kohr, Danielle ^a   Kaps, Manfred ^a   Blaes, Franz ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

MHC class I; MHC class II; Statins

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; GAMMA INTERFERON; GGTI 298; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; SIMVASTATIN;

ANTIGEN EXPRESSION; ATHEROGENESIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DOWN REGULATION; DRUG EFFECT; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNOMODULATION; MORBIDITY; MYOPATHY; MYOSITIS; NONHUMAN; PRENYLATION; TREATMENT RESPONSE;

EID: 69949126871     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04646.x     Document Type: Conference Paper

References (36)

1. Ginsberg, H.N. 1998. Effects of statins on triglyceride metabolism. Am. J. Cardiol. 81: 32B-35B.
2. Greenwood, J., L. Steinman & S.S. Zamvil. 2006. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6: 358-370.
3. Greenwood, J. & J.C. Mason. 2007. Statins and the vascular endothelial inflammatory response. Tr e n d s Immunol. 28: 88-98.
4. Weitz-Schmidt, G., et al. 2001. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7: 687-692.
5. Zhang, F.L. & P.J. Casey. 1996. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65: 241-269.
6. Takai, Y., T. Sasaki & T. Matozaki. 2001. Small GTP-binding proteins. Physiol. Rev. 81: 153-208.
7. Weber, M.S., et al. 2006. Statins in the treatment of central nervous system autoimmune disease. J. N e u-roimmunol. 178: 140-148.
8. Wagner, A.H., O. Schwabe & M. Hecker.2002. Ator-vastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br. J. Pharmacol. 136: 143-149.
9. Aktas, O., et al. 2003. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 197: 725-733.
10. Youssef, S. et al. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84.
11. Azuma, R.W., et al. 2004. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Car-diovasc. Res. 64: 412-420.
12. Greenwood, J., et al. 2003. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune en-cephalomyelitis. Faseb J. 17: 905-907.
13. Nath, N., et al. 2004. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J. Immunol. 172: 1273-1286.
14. Yilmaz, A., et al. 2004. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172: 85-93.
15. Kuipers, H.F., et al. 2005. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing mi-crodomains. Hum. Immunol. 66: 653-665.
16. Kwak, B., et al. 2000. Statins as a newly recognized type of immunomodulator. Nat. Med. 6: 1399-1402.
17. Belliard, G., S. Coupel & B. Charreau. 2005. Fluvas-tatin affects HLA class I expression on endothelial cells. Nephrol. Ther. 1: 221-227.
18. Mach, F. 2002. Statins as immunomodulators. Transpl. Immunol. 9: 197-200.
19. Sriram, S. & L. Steinman. 1983. Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes. J. Exp. Med. 158: 1362-1367.
20. Waldor, M.K., et al. 1984. Disappearance and reappearance of B cells after in vivo treatment with monoclonal anti-I-A antibodies. Proc. Natl. Acad. Sci. USA 81: 2855-2858.
21. Reith, W., S. LeibundGut-Landmann & J.M. Wald-burger. 2005. Regulation of MHC class II gene expression by the class II transactivator. Nat. Rev. Immunol. 5: 793-806.
22. Lee, S.J., H. Qin & E.N. Benveniste. 2008. The IFN-gamma-induced transcriptional program of the CI-ITA gene is inhibited by statins. Eur. J. Immunol. 38: 2325-2336.
23. Ehrenstein, M.R., E.C. Jury & C. Mauri. 2005. Statins for atherosclerosis-as good as it gets? N. Engl. J. M e d . 352: 73-75.
24. Jury, E.C. & M.R. Ehrenstein. 2005. Statins: im-munomodulators for autoimmune rheumatic disease? Lupus 14: 192-196.
25. Needham, M., et al. 2007. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul. Disord. 17: 194-200.
26. Nagaraju, K. 2005. Role of major histocompatibility complex class I molecules in autoimmune myositis. Curr. Opin. Rheumatol. 17: 725-730.
27. Nagaraju, K., et al. 2000. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc. Natl. Acad. Sci. USA 97: 9209-9214.
28. Singh, P. 2008. Statins potentiate interferon-γinduced expression of MHC class I in TE671 rhab-domyosarcoma cells, but not in primary skeletal muscle cells. Manuscript submitted.
29. Tilkin-Mariame, A.F., et al. 2005. Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimu-latory molecule expression. Faseb J. 19: 1513-1515.
30. Raghavan, M., et al. 2008. MHC class I assembly: out and about. Trends Immunol. 29(9): 436-443.
31. Elliott, T. 1997. Transporter associated with antigen processing. Adv. Immunol. 65: 47-109.
32. Driscoll, J., et al. 1993. MHC-linked LMP gene products specifically alter peptidase activities of the pro-teasome. Nature 365: 262-264.
33. Gaczynska, M., et al. 1994. Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc. Natl. Acad. Sci. USA 91: 9213-9217.
34. Groettrup, M., et al. 1995. The interferon-gamma-inducible 11 S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20 S proteasome in vitro. J. Biol. Chem. 270: 23808-23815.
35. Niedermann, G., et al. 1995. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 2: 289-299.
36. Tanaka, K. 1994. Role of proteasomes modified by interferon-gamma in antigen processing. J. Leukoc. Biol. 56: 571-575.